Role of arterial hypertension as a predictive marker for bevacizumab efficacy in recurrent glioblastoma - a prospective analysis

Acta Oncol. 2014 Apr;53(4):572-5. doi: 10.3109/0284186X.2013.852240. Epub 2013 Nov 13.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bevacizumab
  • Biomarkers / analysis*
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / mortality
  • Brain Neoplasms / pathology
  • Female
  • Follow-Up Studies
  • Glioblastoma / drug therapy*
  • Glioblastoma / mortality
  • Glioblastoma / pathology
  • Humans
  • Hypertension / chemically induced
  • Hypertension / diagnosis*
  • Hypertension / mortality
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / chemically induced
  • Neoplasm Recurrence, Local / diagnosis*
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Staging
  • Prognosis
  • Prospective Studies
  • Survival Rate
  • Young Adult

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Biomarkers
  • Bevacizumab